You just read:

Grünenthal and Akashi Therapeutics Inc. Announce Joint Drug Development Program for HT-100 in the Treatment of Patients with Duchenne Muscular Dystrophy (DMD)

News provided by

Grunenthal Pharma GmbH & Co. KG.

Jan 08, 2016, 07:00 ET